- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03291236
Survival Outcomes of Uterine Cervical Malignancies in Chinese Population
February 7, 2018 updated by: Lei Li
This study aims to determine survival outcomes (overall survival and progression-free survival) of primary malignancies of uterine cervix in China and relevant risk factors in a prospective cohort study.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
5000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
China/Beiing
-
Beijing, China/Beiing, China, 100000
- Recruiting
- Lei Li
-
Contact:
- Lei L Li, MD
- Phone Number: +86 13911988831
- Email: lileigh@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
All patients with primary malignancies of uterine cervix in China.
Description
Inclusion Criteria:
- Primary malignancies of uterine cervix.
Exclusion Criteria:
- Secondary malignancies of uternie cervix.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival
Time Frame: 5 years
|
Duration from diagnosis to recurrence
|
5 years
|
|
Progression-free survival
Time Frame: 5 years
|
Duration from last treatment after remission to recurrence
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Lei Li, MD, Peking Union Medical College Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2017
Primary Completion (Anticipated)
January 1, 2022
Study Completion (Anticipated)
January 1, 2023
Study Registration Dates
First Submitted
September 20, 2017
First Submitted That Met QC Criteria
September 20, 2017
First Posted (Actual)
September 25, 2017
Study Record Updates
Last Update Posted (Actual)
February 8, 2018
Last Update Submitted That Met QC Criteria
February 7, 2018
Last Verified
February 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SOCM-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uterine Cervical Neoplasms
-
Huazhong University of Science and TechnologyQilu Hospital of Shandong University; Third Military Medical University; Women... and other collaboratorsRecruitingCervical Cancer | Uterine Cervical Cancer | Uterine Cervical NeoplasmChina
-
University of AarhusRecruitingUterine Cervical Neoplasm | Mass Screening | Uterine Cervical Disease | Uterine NeoplasmDenmark
-
Siriwan Tangjitgamol, MDPrince of Songkla University; National Research Council of Thailand; Chiang Mai... and other collaboratorsUnknownUterine Cervical CancerThailand
-
Tampere UniversityGlaxoSmithKline; FinnMedi OyEnrolling by invitation
-
Huazhong University of Science and TechnologyZhejiang University; Wuhan Central HospitalUnknownCervical Cancer | Uterine Cervical Neoplasms | Uterine Cervical CancerChina
-
Washington University School of MedicineTerminatedCervical Cancer | Uterine Cervical Neoplasms | Uterine Cervical CancerUnited States
-
Shanghai First Maternity and Infant HospitalUnknownCervical Cancer | Cervical Precancer
-
University Hospitals Cleveland Medical CenterCompletedUterine Cervical Dysplasia | Uterine Cervical Cancer | Uterine Cervical Neoplasia | Uterine Cervical Intraepithelial Neoplasia
-
Huazhong University of Science and TechnologyShandong University; Zhejiang UniversityCompletedCervical Cancer | Uterine Cervical Neoplasms | Uterine Cervical CancerChina
-
Center Eugene MarquisCompleted
Clinical Trials on Follow-up for death and recurrence of patients
-
Lei LiRecruitingEndometrial Neoplasms | SurvivalChina
-
Lei LiUnknown
-
Sohag UniversityRecruiting
-
St. James's Hospital, IrelandKarolinska Institutet; St Mary's Hospital, Paddington, LondonCompletedEsophageal Cancer | Chemoradiation | Chemotherapy | Surgery | Metastatic Cancer | Radiation | Recurrent Esophageal CancerSweden, Ireland, United Kingdom
-
Fundación Santa Fe de BogotaCompleted
-
Ostfold Hospital TrustNot yet recruiting
-
Beijing Neurosurgical InstituteRecruitingCerebral Hemorrhage | Artificial Intelligence | PrognosisChina
-
Centre Hospitalier René DubosCompleted
-
Euresist Network GEIEHeinrich-Heine University, Duesseldorf; University of Rome Tor Vergata; St Mary... and other collaboratorsRecruiting
-
Helixmith Co., Ltd.CompletedDiabetic Neuropathy, Painful | Painful Diabetic NeuropathyUnited States